SCHEMBL6038520

SCHEMBL6038520

Cc1ccc(S(=O)(=O)Nc2ncc(-c3cc(F)cc(F)c3)nc2OCc2cccnc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 2/20 0.47
SCN9A Q15858 1/20 0.44
SQOR Q9Y6N5 1/20 0.43
CKS1B P61024 1/20 0.43
SKP2 Q13309 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 2/20 0.41
KCNA5 P22460 2/20 0.41
NAMPT P43490 5/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038463 0.93 CCR4 (0.48) CCR4SCN9ASQORPOLBHTT
SCHEMBL6039130 0.92 CCR4 (0.48) CCR4SCN9ASQORPOLBHTT
SCHEMBL6038813 0.91 CCR4 (0.52) CCR4SCN9ACKS1BSKP2POLB
SCHEMBL6038816 0.89 CCR4 (0.50) CCR4SCN9ACKS1BSKP2POLB
SCHEMBL6039140 0.89 MEN1 (0.46) CCR4SCN9APOLBHTTKDM4E
SCHEMBL6038681 0.89 CCR4 (0.49) CCR4SCN9APOLBHTTKDM4E
SCHEMBL6038976 0.88 CCR4 (0.50) CCR4SCN9ACKS1BSKP2POLB
SCHEMBL6038468 0.88 CCR4 (0.47) CCR4SCN9APOLBHTTKDM4E
SCHEMBL6038479 0.87 POLB (0.49) CCR4SCN9ACKS1BSKP2POLB
SCHEMBL6038916 0.87 CCR4 (0.49) CCR4SCN9ACKS1BSKP2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 CCR4 1/4885SCN9A 2242/4885SQOR 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.